- Home
- FCN vs GH Comparison
FCN vs GH Comparison
Compare FCN & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCN
- GH
- Stock Information
- Founded
- FCN 1982
- GH 2011
- Country
- FCN United States
- GH United States
- Employees
- FCN N/A
- GH N/A
- Industry
- FCN Professional Services
- GH Medical Specialities
- Sector
- FCN Consumer Discretionary
- GH Health Care
- Exchange
- FCN Nasdaq
- GH Nasdaq
- Market Cap
- FCN 5.1B
- GH 4.9B
- IPO Year
- FCN 1996
- GH 2018
- Fundamental
- Price
- FCN $166.81
- GH $95.05
- Analyst Decision
- FCN Hold
- GH Strong Buy
- Analyst Count
- FCN 2
- GH 22
- Target Price
- FCN $169.00
- GH $74.32
- AVG Volume (30 Days)
- FCN 509.0K
- GH 3.2M
- Earning Date
- FCN 10-23-2025
- GH 10-29-2025
- Dividend Yield
- FCN N/A
- GH N/A
- EPS Growth
- FCN N/A
- GH N/A
- EPS
- FCN 7.77
- GH N/A
- Revenue
- FCN $3,693,035,000.00
- GH $902,569,000.00
- Revenue This Year
- FCN $1.58
- GH $28.28
- Revenue Next Year
- FCN $6.52
- GH $23.00
- P/E Ratio
- FCN $21.46
- GH N/A
- Revenue Growth
- FCN N/A
- GH 30.38
- 52 Week Low
- FCN $149.31
- GH $23.27
- 52 Week High
- FCN $209.13
- GH $100.22
- Technical
- Relative Strength Index (RSI)
- FCN 58.97
- GH 76.45
- Support Level
- FCN $161.20
- GH $68.02
- Resistance Level
- FCN $170.98
- GH $100.21
- Average True Range (ATR)
- FCN 4.64
- GH 4.46
- MACD
- FCN 1.19
- GH 2.94
- Stochastic Oscillator
- FCN 80.33
- GH 85.75
About FCN FTI Consulting Inc.
FTI Consulting Inc is a firm that generates its sales by providing professional business advisory services to customers. The company operates through five segments, namely corporate finance, forensic and litigation consulting, economic consulting, technology, and strategic communications. The company generates the majority of its revenue from the Corporate finance segment. Customers of the company come from a wide array of sectors, including construction, energy and power, environmental, financial institutions, healthcare and life science, insurance, real estate and infrastructure, retail and consumer products, telecom, media, and technology. The majority of the company's revenue is derived from serving customers in the United States.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.